Latest Oesophageal Cancer News

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Invion Limited has secured a $2 million non-dilutive grant from the South Korean government to advance preclinical studies for oesophageal cancer, expanded its global Photosoft technology license, and raised $1.3 million via convertible notes to strengthen its financial position.

Invion Limited has raised $1.3 million through a convertible note offering anchored by its CEO and a major shareholder, aiming to fast-track clinical trials for multiple cancer treatments.

Percheron Therapeutics has reported encouraging safety and efficacy signals from its HMBD-002 phase I trial, and outlined an innovative modular phase II trial design targeting multiple cancers in 2026.

Invion Limited’s partner Hanlim Pharm, backed by South Korea’s government grant, has secured up to A$2 million in non-dilutive funding to advance preclinical studies of HL270 for oesophageal cancer, paving the way for human trials in Australia.

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.

Invion Limited has progressed its Photosoft clinical programs with new patient dosing and an expanded collaboration with Hanlim Pharm, backed by a successful $2 million share placement to accelerate development.